Resumen
Lung cancer therapeutics have dramatically improved in recent years. Indeed, precision oncology could be exemplified by non-small cell lung cancer (NSCLC), with molecular profiling and programmed death ligand 1 (PD-L1) immunohistochemical expression representing an integral part of its tailored treatment. The present narrative review aims to highlight the promising role of artificial intelligence (AI) technologies in the optimal, patient-centered management of NSCLC, by distilling as well as interpreting big data.